Shandong Lukang Pharmaceutical Gains Approval for Drug Raw Material Application

Stock News

Aug 12

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SH) has announced that it received a "Chemical Raw Material Drug Listing Application Approval Notice" from the National Medical Products Administration concerning brexpiprazole, authorizing the drug's market entry.

Brexpiprazole is a second-generation atypical antipsychotic. Due to its balanced modulation of the dopamine and serotonin systems, it can achieve both efficacy and safety. It is the only oral antipsychotic globally where all side effect risks show no significant difference from placebo.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1194168366"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194168366\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194168366?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-12 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194168366","market":"sh","top_or_hot":-1,"title":"Shandong Lukang Pharmaceutical Gains Approval for Drug Raw Material Application","media":"Stock News","content":"<p><b>Shandong Lukang Pharmaceutical Co.,Ltd.</b> (<b>600789.SH</b>) has announced that it received a \"Chemical Raw Material Drug Listing Application Approval Notice\" from the National Medical Products Administration concerning brexpiprazole, authorizing the drug's market entry.<br><br>Brexpiprazole is a second-generation atypical antipsychotic. Due to its balanced modulation of the dopamine and serotonin systems, it can achieve both efficacy and safety. It is the only oral antipsychotic globally where all side effect risks show no significant difference from placebo.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Lukang Pharmaceutical Gains Approval for Drug Raw Material Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Lukang Pharmaceutical Gains Approval for Drug Raw Material Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-12 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shandong Lukang Pharmaceutical Co.,Ltd.</b> (<b>600789.SH</b>) has announced that it received a \"Chemical Raw Material Drug Listing Application Approval Notice\" from the National Medical Products Administration concerning brexpiprazole, authorizing the drug's market entry.<br><br>Brexpiprazole is a second-generation atypical antipsychotic. Due to its balanced modulation of the dopamine and serotonin systems, it can achieve both efficacy and safety. It is the only oral antipsychotic globally where all side effect risks show no significant difference from placebo.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1194168366","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194168366","pubTimestamp":1786526906,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SH) has announced that it received a \"Chemical Raw Material Drug Listing Application Approval Notice\" from the National Medical Products Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600789":"鲁抗医药","BK0239":"医药制造","BK0188":"融资融券","BK0168":"禽流感","IPOS":"Renaissance International IPO ETF","BK0046":"生物疫苗"},"translate_title":"山东鲁抗制药获得药品原料药申请批复","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600789":1,"IPOS":1},"content_text":"Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SH) has announced that it received a \"Chemical Raw Material Drug Listing Application Approval Notice\" from the National Medical Products Administration concerning brexpiprazole, authorizing the drug's market entry.Brexpiprazole is a second-generation atypical antipsychotic. Due to its balanced modulation of the dopamine and serotonin systems, it can achieve both efficacy and safety. It is the only oral antipsychotic globally where all side effect risks show no significant difference from placebo.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}